Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359602 | 0.78 | CHRM4 (0.46) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL12359785 | 0.78 | CHRM4 (0.41) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL1098102 | 0.75 | NR1H2 (0.62) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL31521005 | 0.75 | NR1H2 (0.62) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL12359781 | 0.75 | CHRM4 (0.49) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL3571209 | 0.75 | HDAC1 (0.53) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL29940282 | 0.75 | HDAC1 (0.53) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL14230676 | 0.74 | DRD2 (0.55) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL12511778 | 0.74 | CHRM4 (0.46) | CHRM4DRD2HTR7NR1H2ESR2 | |
| SCHEMBL23063860 | 0.74 | DRD2 (0.52) | CHRM4DRD2HTR7NR1H2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003624-B2 | Functionally selective ALPHA2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003624-B2 | Functionally selective ALPHA2C adrenoreceptor agonists | SCHERING CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1945626-B1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORP (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803828-B2 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING-PLOUGH CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2008100457-A2 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | SCHERING CORPORATION | 2007-05-03 | — | — | US | disclosed |
| WO-2007024944-A1 | IMIDAZOLE DERIVATIVES AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS | SCHERING CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027100-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | CHRM4 96/4885DRD2 130/4885HTR7 83/4885 |
| US-20070099872-A1 | Functionally selective alpha2C adrenoreceptor agonists | ADRA2C, ADRB2, ADRA2A | CHRM4 96/4885DRD2 130/4885HTR7 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.